Research article summary (published 29 Apr 2007):

Update on drugs for hyperactivity in childhood.

Full Abstract

In 2001, we concluded that methylphenidate or dexamfetamine can be useful adjunctive therapy for children with severe hyperactivity in whom non-drug approaches alone have been inadequate. Since then, atomoxetine (pronounced a-toe-moks-e-teen; Strattera - Lilly) and three modified-release formulations of methylphenidate have been launched for attention deficit hyperactivity disorder (ADHD). Here we reconsider drugs for ADHD in childhood, focusing on the newer products.

Author information

Journal and publication information

Publication Type: Journal Article; Review

Journal: Drug and therapeutics bulletin (Drug Ther Bull), published in England. (Language: eng)

Reference: 2007-May; vol 45 (issue 5) : pp 37-40

Dates: Created 2007/05/31; Completed 2007/11/21; Revised 2008/01/04;

PMID: 17536494, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

Comments and Corrections

ErratumIn: Drug Ther Bull. 2007 Aug;45(8):64.

ErratumIn: Drug Ther Bull. 2007 Nov;45(11):88.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adrenergic Uptake Inhibitors - economics; therapeutic use Attention Deficit Disorder with Hyperactivity - drug therapy; economics Central Nervous System Stimulants - economics; therapeutic use Child Delayed-Action Preparations Dextroamphetamine - economics; therapeutic use

Dextroamphetamine - economics; therapeutic use Drug Costs Humans Methylphenidate - economics; therapeutic use Propylamines - economics; therapeutic use Treatment Outcome

Associated Chemicals: Adrenergic Uptake Inhibitors (0) ; Central Nervous System Stimulants (0) ; Delayed-Action Preparations (0) ; Propylamines (0) ; Methylphenidate (113-45-1) ; Dextroamphetamine (51-64-9) ; atomoxetine (83015-26-3)

Related articles

These are the highest related articles currently in the database:

• A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. 29 Apr 2008
• Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. 30 Jul 2004
• Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. 30 Aug 2007
• [The costs of drugs against ADDH should be reduced] 24 Jun 2003
• Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE). 12 Feb 2008
• Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. 30 Oct 2001
• [Methylphenidate of retard forms in children and adolescents with ADHD - an overview] 19 Dec 2007
• Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. 29 Nov 2004
• Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness. 29 Sep 2007
• Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. 30 Jan 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.